China Study: Your Gut Bacteria May Predict Fiber's Effect on Prediabetes

A Study from China Reveals Why Fiber Works for Some Prediabetics — But Not Others

A study from China has uncovered a striking finding that could reshape how doctors advise prediabetic patients about diet: whether dietary fiber actually improves your blood sugar may depend almost entirely on the unique makeup of bacteria living in your gut.

Researchers at Shanghai General Hospital and Shanghai Jiao Tong University enrolled 802 adults with prediabetes in a six-month randomized trial. Half received standard care — education and general dietary guidance — while the other half followed a structured dietary fiber intervention. On the surface, the two groups showed no significant overall difference in HbA1c (a key measure of average blood sugar over roughly three months). That result alone would seem discouraging. But the real discovery came when researchers dug deeper.

The Gut Microbiome Makes All the Difference

Using a machine learning model, the team sorted participants into four metabolic clusters based on age, BMI, HbA1c, and insulin resistance markers. Two of those clusters — patients with more advanced metabolic stress and specific gut bacteria profiles — showed meaningful improvements in blood sugar control from the fiber diet. The other two clusters showed little to no benefit.

In US terms, the patients most likely to benefit had starting HbA1c values in the prediabetes range of approximately 100–125 mg/dL (fasting glucose equivalent) or HbA1c between 5.7% and 6.4%, mirroring American Diabetes Association (ADA) prediabetes thresholds. The researchers then built a clinical decision tool — a "microbiome-based score" — capable of identifying in advance which individuals would respond to fiber therapy.

Why This International Perspective Matters

China has the world's largest population of people with diabetes — over 140 million — giving Chinese research institutions access to massive, diverse clinical trial populations that can detect subtle patterns US studies often miss. This 802-person trial, one of the largest gut microbiome–diet intervention studies in prediabetes ever conducted, offers statistical power that lends real credibility to its conclusions.

Why This Matters for US Patients

In the United States, approximately 98 million adults have prediabetes, and the ADA currently recommends increased dietary fiber as a broad lifestyle intervention for everyone in this group. This Chinese research challenges the one-size-fits-all approach. If a simple microbiome-based score could identify the roughly half of prediabetic patients who won't benefit from fiber-focused diets, American clinicians could redirect those patients toward interventions that actually work for their biology — saving time, effort, and frustration.

The study also validates growing US interest in the gut-metabolism connection. Research institutions like the NIH Human Microbiome Project have laid groundwork here, but this Chinese trial moves the science significantly closer to a clinical tool doctors could realistically use in practice.

What This Means Right Now

Microbiome testing is not yet a standard part of prediabetes care in the US, and the scoring model developed in Shanghai requires further validation in diverse Western populations before widespread adoption. However, the findings strongly support asking your endocrinologist about personalized nutrition approaches — especially if you've tried increasing fiber without seeing blood sugar improvement.

Original Study: Song, Feng, Ma et al. "Gut microbiome predicts personalized responses to dietary fiber in prediabetes: a randomized, open-label trial." Nature Communications, 2025. DOI: 10.1038/s41467-025-66498-x. PMID: 41390484.